Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 418.81% from the stock’s previous close. HC Wainwright also issued estimates for Kura Oncology’s Q1 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

A number of other research analysts have also recently weighed in on KURA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Wedbush lifted their price target on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Finally, Scotiabank reduced their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Price Performance

KURA opened at $7.71 on Thursday. The company’s 50 day simple moving average is $8.16 and its 200 day simple moving average is $13.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The stock has a market capitalization of $599.56 million, a PE ratio of -3.27 and a beta of 0.78.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. As a group, sell-side analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Kura Oncology by 7.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock worth $1,147,000 after acquiring an additional 9,050 shares during the last quarter. Woodline Partners LP grew its position in shares of Kura Oncology by 20.6% during the fourth quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock worth $1,504,000 after acquiring an additional 29,497 shares during the last quarter. Velan Capital Investment Management LP bought a new position in shares of Kura Oncology during the fourth quarter worth about $1,306,000. Squarepoint Ops LLC bought a new position in shares of Kura Oncology during the fourth quarter worth about $799,000. Finally, Two Sigma Advisers LP grew its position in shares of Kura Oncology by 147.1% during the fourth quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock worth $2,110,000 after acquiring an additional 144,201 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.